What were the main drivers of Abbott's sales growth in the second quarter of 2007?

Abbott's sales growth in the second quarter of 2007 was primarily driven by the acquisitions of Guidant's vascular intervention and endovascular solutions businesses (completed in April 2006) and Kos Pharmaceuticals Inc. (completed in December 2006). Strong performance in the Pharmaceutical Products segment, particularly from products like HUMIRA, and increased sales in the Vascular Products segment also contributed significantly. A weaker U.S. dollar also had a positive impact on international sales.

How did the company's profitability change compared to the prior year's second quarter?

Profitability significantly improved. Net earnings increased from $612.2 million in the second quarter of 2006 to $988.7 million in the second quarter of 2007. This substantial increase is reflected in the diluted EPS, which rose from $0.40 to $0.63.

What is the status of the diagnostic business that was classified as 'held for sale'?

Abbott announced on July 11, 2007, that the agreement to sell its core laboratory diagnostics business to GE was terminated. Therefore, these assets and liabilities will no longer be classified as held for sale starting in the third quarter of 2007. The company had previously discontinued depreciation and amortization on these assets effective January 17, 2007, and this will be reversed in the third quarter.

Are there any significant legal or regulatory issues that investors should be aware of?

Abbott is involved in various legal proceedings, including patent disputes related to products like Depakote and Omnicef, and investigations concerning pricing information for certain drugs sold to Medicare and Medicaid programs. While management believes the ultimate disposition of these matters should not have a material adverse effect on the company's financial position, cash flows, or results of operations, they noted that resolutions in pricing information cases could be material to cash flows or results of operations for a quarter.

ABT 10-Q Quarterly Report Q2 FY2007 — Revenue, Net Income, EPS

Summary

Abbott Laboratories (ABT) reported strong financial performance for the quarter ending June 30, 2007, with net sales reaching $6.37 billion, a significant increase of 15.8% year-over-year. This growth was driven by robust performance across its key segments, particularly Pharmaceuticals and Vascular Products, bolstered by recent acquisitions including Guidant's vascular businesses and Kos Pharmaceuticals. Net earnings also saw a substantial rise to $988.7 million, translating to a diluted EPS of $0.63. The company also highlighted its ongoing commitment to returning value to shareholders, evidenced by continued share repurchases and dividend payments. Management expressed confidence in future growth, supported by a healthy product pipeline and strategic acquisitions. While facing some ongoing litigation and regulatory scrutiny, as is common in the pharmaceutical industry, Abbott appears to be navigating these challenges effectively, with management believing the outcomes will not materially impact the company's financial position.

Key Highlights

1Net sales for the quarter reached $6.37 billion, an increase of 15.8% compared to the same period in the prior year.
2Net earnings for the quarter were $988.7 million, with diluted earnings per share (EPS) at $0.63.
3The Pharmaceutical Products segment experienced a 17.2% increase in sales, driven by strong performance in U.S. Specialty and International markets, notably with products like HUMIRA.
4The Vascular Products segment saw a significant 63.3% surge in sales, largely due to the acquisition of Guidant's vascular businesses.
5Abbott repurchased approximately 4.8 million shares of its common stock during the quarter, totaling $4.8 million in value, as part of its ongoing share repurchase program.
6The company declared a cash dividend of $0.325 per common share, reflecting its commitment to shareholder returns.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2007

Summary

Key Highlights

Frequently Asked Questions